24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with the mid-February figures. Across the board, all the selected stocks have seen…
The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected stocks, short interest is down.
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Tuesday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls include GE, Gilead Sciences, Oracle, Under Armour and El Pollo Loco.
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or…
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
In a new report, Stifel analysts highlight their top biotech stocks with strong earnings momentum and possible catalysts to buy right now.
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams of revenue.
